SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Journal of Renin-Angiotensin-Aldosterone System
This Article
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by McMurray, J.
Right arrow Articles by Berry, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by McMurray, J.
Right arrow Articles by Berry, C.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Editorial

Ongoing clinical trials with angiotensin II receptor antagonists in chronic heart failure and myocardial infarction

John McMurray

Clinical Research Initiative in Heart Failure and Department of Medicine & Therapeutics, University of Glasgow, Glasgow, Scotland, UK, j.mcmurray{at}bio.gla.ac.uk

Colin Berry

Clinical Research Initiative in Heart Failure and Department of Medicine & Therapeutics, University of Glasgow, Glasgow, Scotland, UK

Key Words: angiotensin II receptor antagonist • ACE inhibitor • clinical trials • myocardial infarction • heart failure

References

  • The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316: 1429-35.[Abstract]
  • The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293-302.[Abstract]
  • Garg R., Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative group on ACE Inhibitor Trials. JAMA 1995; 273: 1450-6.[Abstract/Free Full Text]
  • Pfeffer MA, Braunwald E., Moye LA, Basta L., Brown EJ, CuddyTE et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992; 327: 669-77.[Abstract]
  • The AIRE Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet 1993; 342: 821-8.[Web of Science][Medline] [Order article via Infotrieve]
  • Kober L.,Torp-Pedersen C., Carlsen JE et al. A clinical trial of the angiotensin converting enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1995; 333:1670-6.[Abstract/Free Full Text]
  • Packer M., Poole-Wilson PA, Armstrong PW et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation 1999; 100: 2312-8.[Abstract/Free Full Text]
  • Pitt B., Zannad F., Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study. N Engl J Med 1999; 341: 709-17.[Abstract/Free Full Text]
  • Gottlieb SS, Dickstein K., Fleck E. et al. Hemodynamic and neurohormonal effects of the angiotensin-II antagonist losartan in patients with congestive heart failure. Circulation 1993: 88: 1602-9.[Abstract/Free Full Text]
  • Crozier I., Ikram H.,Awan N. et al. Losartan in heart failure. Haemodynamic effects and tolerability. Losartan Hemodynamic Study Group. Circulation 1995; 91: 691-7.[Abstract/Free Full Text]
  • Mazayev VP, Fomina IG, Kazakov EN et al. Valsartan in heart failure patients previously untreated with an ACE inhibitor. Int J Cardiol 1998; 65: 239-46.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Parker AB, Azevedo ER, Baird MG et al. ARCTIC: assessment of haemodynamic response in patients with congestive heart failure to telmisartan: a multicentre dose-ranging study in Canada. Am Heart J 1999;138:843-8.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Riegger GAJ, Bouzo H., Petr P. et al. Improvement in exercise tolerance and symptoms of congestive heart failure during treatment with candesartan cilexetil. Circulation 1999; 100: 2224-30.[Abstract/Free Full Text]
  • Havranek EP,Thomas I., Smith WB et al. Dose-related beneficial long-term hemodynamic and clinical efficacy of irbesartan in heart failure. J Am Coll Cardiol 1999; 33(5): 1174-81.[Abstract/Free Full Text]
  • Sharma D., Buyse M., Pitt B., Rucinska EJ the Losartan Heart Failure Mortality Meta-analysis Study Group. Meta-analysis of observed mortality data from all-controlled, double-blind, multiple-dose studies of losartan in heart failure. Am J Cardiol 2000; 85: 187-92.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Pitt B., Poole-Wilson P., Segal R. et al. Effects of losartan versus captopril on mortality in patients with symptomatic heart failure: rationale, design, and baseline characteristics of patients in the Losartan Heart Failure Survival Study - ELITE II. J Card Fail 1999: 5:146-54.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Pitt B., Poole-Wilson P., Segal R. et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study ELITE II. Lancet 2000;355: 1582-7.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Granger B., Ertl G., Kuch J. et al. Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors. Am Heart J 2000; 139: 609-17.
  • Pitt B., Chang P.,Timmermans PBM. Angiotensin-II receptor antagonists in heart failure - Rationale and design of the evaluation of losartan in the elderly (ELITE) trial. Cardiovascular Drugs and Therapy 1995; 9(5): 693-700.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Pitt B., Segal R., Martinez FA et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997; 349: 747-52.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Wolny A., Clozel JP, Rein J. et al. Functional and biochemical analysis of angiotensin II forming pathways in the human heart. Circulation Research 1997; 80: 219-27.[Abstract/Free Full Text]
  • Voors AA, Pinto YM, Buikema H. et al. Dual pathway for angiotensin II formation in human internal mammary arteries. British Journal of Pharmacology 1998; 125: 1028-32.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Padmanabhan N., Jardine AG, McGrath JC, Connell JMC. Angiotensin-converting-enzyme-independent contraction to angiotensin I in human resistance arteries. Circulation 1999; 99:2914-2920.[Abstract/Free Full Text]
  • Tsuyuki RT,Yusuf S., Rouleau JL et al. Combination neurohormonal blockade with ACE inhibitors, angiotensin II antagonists and beta-blockers in patients with congestive heart failure: Design of the Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) Pilot Study. Canadian Journal of Cardiology 1997; 13: 1166-1174.[Web of Science][Medline] [Order article via Infotrieve]
  • McKelvie RS,Yusuf S., Pericak D. et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation 1999; 100: 1056-64.[Abstract/Free Full Text]
  • Jones B., Jarvis P., Lewis JA, Ebbutt AF Trials to assess equivalence: the importance of rigorous methods. Br Med J 1996; 313:36-9.[Free Full Text]
  • Siegel JP Equivalence and non-inferiority trials. Am Heart J 2000; 139:166-70.[CrossRef]
  • Gainer JV, Morrow JD, Loveland A., King DJ, Brown NJ Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects. N Engl J Med 1998; 339: 1285-92.[Abstract/Free Full Text]
  • Davie AP, Dargie HJ, McMurray JJ Role of bradykinin in the vasodilator effects of losartan and enalapril in patients with heart failure. Circulation 1999; 100: 268-73.[Abstract/Free Full Text]
  • Baruch L.,Anand I., Cohen IS, Ziesche S., Judd D., Cohn JN Augmented short- and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure. Circulation 1999; 99: 2658-64.[Abstract/Free Full Text]
  • Tonkon M.,Awan N., Niazi et al. A study of the efficacy and safety of irbesartan in combination with conventional therapy, including ACE inhibitors, in heart failure. Irbesartan Heart Failure Group. Int J Clin Pract 2000; 54:11-4,16-8.[Medline] [Order article via Infotrieve]
  • Jorde UP, Ennezat PV, Lisker J. et al. Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure. Circulation 2000; 101: 844-6.[Abstract/Free Full Text]
  • Hamroff G., Katz SD, Mancini D. et al. Addition of angiotensin II receptor blockade to maximal angiotensin-converting-enzyme inhibition improves exercise capacity in patients with severe congestive heart failure. Circulation 1999; 99: 990-2.[Abstract/Free Full Text]
  • Senni M.,Tribouilloy CM, Rodeheffer RJ et al. Congestive heart failure in the community - A study of all incident cases in Olmsted County, Minnesota, in 1991. Circulation 1998; 98: 2282-9.[Abstract/Free Full Text]
  • Vasan RS, Larson MG, Benjamin EJ, Evans JC, Reiss CK, Levy D. Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction - Prevalence and mortality in a population-based cohort.J Am Coll Cardiol 1999; 33: 1948-55.[Abstract/Free Full Text]
  • Cohn JN,Archibald DG, Ziesche S. et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. N Engl J Med 1986; 314:1547-52.[Abstract]
  • Cohn JN, Johnson G., Ziesche S. et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991; 325: 303-10.[Abstract]
  • Benedict CR,Weiner DH, Johnstone DE et al. Comparative neurohormonal responses in patients with preserved and impaired left ventricular ejection fraction - Results of the studies of left ventricular dysfunction (SOLVD) Registry. J Am Coll Cardiol 1993;212:A146-A153.
  • Mindlen F., Nordaby R., Ruiz M. et al. The HOPE (Heart Outcomes Prevention Evaluation) Study: The design of a large, simple randomized trial of an angiotensin converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events.Canadian Journal of Cardiology 1996; 12: 127-37.[Web of Science][Medline] [Order article via Infotrieve]
  • Yusuf S., Sleight P., Pogue J. et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342:145-53.[Abstract/Free Full Text]
  • Cohn JN, Tognoni G., Glazer RD, Spormann D., Hester A. Rationale and design of the Valsartan Heart Failure Trial: a large multinational trial to assess the effects of valsartan, an angiotensin-receptor blocker, on morbidity and mortality in chronic congestive heart failure. J Card Fail 1999 Jun: 5: 155-60.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Pfeffer M., Swedberg K., Granger C. et al. Candesartan in heart failure - assessment of reduction in mortality and morbidity (CHARM): rationale and design. Charm-Programme Investigators.J Cardiac Failure 1999; 5: 276-82.[CrossRef][Medline] [Order article via Infotrieve]
  • Dickstein K., Kjekshus J. Comparison of the effects of losartan and captopril on mortality in patients after acute myocardial infarction: The OPTIMAAL trial design. Am J Card 1999; 83: 477-81.[CrossRef][Medline] [Order article via Infotrieve]
  • Pfeffer MA, McMurray J., Leizorovicz A. et al. Valsartan in acute myocardial infarction trial - VALIANT: rationale and design. Am Heart J 2000 (in press).

Journal of Renin-Angiotensin-Aldosterone System, Vol. 1, No. 2, 131-136 (2000)
DOI: 10.3317/jraas.2000.015
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?



This Article
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by McMurray, J.
Right arrow Articles by Berry, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by McMurray, J.
Right arrow Articles by Berry, C.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Advertisement